Regulatory aspects on repurposing of drugs in the management of COVID-19

  • Priyansha Bhatia
  • Akash Chauhan
  • Gagan Porwal
  • Vikesh Shukla Amity university, India

Abstract

Drug repurposing involves the disquisition of using medicines for new remedial purposes. With the increasing waste production, given the costs and tiresome pace of new medicine search, repurposing of medicines already in the market to treat all kinds of conditions is decreasingly getting a selective approval because uses the composites that have been de-risked, with lesser development costs and shorter timelines of developing the drug. Colourful and experimental data approaches have been used for the identification of the medicines to be repurposed. There are also major technical and non-supervisory challenges that need to be addressed. In this review, we present the different kinds of approaches used for medicine repurposing, study the challenges faced by the scientists during repurposing as well as recommend ways by which these challenges could be overcome to help realize the full potential of medicine repurposing. Drug displacing is the repurposing of an already existing medicine for the treatment of a different complaint or medical condition than that for which it was firstly developed. This is one line of scientific exploration which is being pursued to develop safe and effective COVID-19 treatments. Other exploration directions include the discovery of a COVID-19 vaccine and convalescent tube transfusion. Several being antiviral specifics, preliminarily developed or used as treatments for SARS, MERS, HIV/ AIDS, and malaria, have been delved as implicit COVID‐19 treatments, with some moving into clinical trials. Monoclonal antibodies under disquisition for repurposing include anti-IL-6 agents (tocilizumab) and anti-IL-8 (BMS-986253). This is in resemblance to new monoclonal antibody medicines developed specifically for COVID-19.

Keywords: Drug repurposing, COVID-19, Clinical trials, SARS, Monoclonal Antibodies

Downloads

Download data is not yet available.

References

1. Tracking SARS-CoV-2 variants [Internet]. WHO; 2022 [cited 2022 Jan 02]. Available from:
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
2. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293-2303
3. Talevi A. Drug Repurposing, Reference Module in Biomedical Sciences. Elsevier;2018. ISBhttp://ijdra.com/index.php/journal/workflow/index/503/5#N 9780128012383
4. Vaishali Gupte, Rashmi Hegde, Sandesh Sawant, Kabil Kalathingal, Sonali Jadhav, Rohit Malabade, Jaideep Gogtay. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infectious Diseases. 2022; 22:1.
5. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018;9(2):e00221-18-e00221-18
6. Schaper C. A Mechanism of Action for Hydroxychloroquine and Azithromycin to Inhibit Coronavirus Disease COVID-19. ChemRxiv. Cambridge: Cambridge Open Engage; 2020
7. Xu J, Cao B. Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. Eur Respir J. 2022 Jan 6;59(1):2102002. doi: 10.1183/13993003.02002-2021. PMID: 34326192; PMCID: PMC8340617.
8. Sherchan R, Cannady, Jr P. Casirivimab. 2022 Feb 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 34283490.
9. Sherchan R, Cannady, Jr P. Imdevimab. 2022 Feb 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 34283431.
10. Dhand, Abhay MD1; Lobo, Stephen A. MD1; Wolfe, Kevin PhD2; Feola, Nicholas PharmD3; Lee, Leslie PharmD3; Nog, Rajat MD1; Chen, Donald MD1; Glicklich, Daniel MD1; Diflo, Thomas MD2; Nabors, Christopher MD, PhD1.Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience, Transplantation. 2021 Jul; 105(7):e68-e69
doi: 10.1097/TP.0000000000003737
11. Kmietowicz Z. Covid-19: WHO recommends baricitinib and sotrovimab to treat patients. BMJ. 2022; 376:o97. doi:10.1136/bmj.o97
12. Intellectual Property India. The Patents Act, 1970 [Internet]. ipindia; 2005 [cited 2022 Jan 02]. Available from:
https://ipindia.gov.in/writereaddata/Portal/IPOAct/1_113_1_The_Patents_Act_1970_-_Updated_till_23_June_2017.pdf
13. Roin BN. Solving the problem of new uses by creating incentives for private industry to repurpose off-patent drugs. Mich St L Rev. [Internet]. petrieflom; 2014 Sep 15 [cited 2022 Jan 04]. Available from:
https://petrieflom.law.harvard.edu/assets/publications/Roin_Solving_the_Problem_of_New_Uses.pdf
Statistics
241 Views | 220 Downloads
How to Cite
Bhatia, P., A. Chauhan, G. Porwal, and V. Shukla. “Regulatory Aspects on Repurposing of Drugs in the Management of COVID-19”. International Journal of Drug Regulatory Affairs, Vol. 10, no. 1, Mar. 2022, pp. 1-13, doi:10.22270/ijdra.v10i1.503.